6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies

6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies

Quick Answer: Diabetes mellitus is a chronic metabolic disorder of carbohydrate, protein, and fat metabolism characterized by persistent hyperglycemia resulting from insulin deficiency, insulin resistance, or both. In Ghana, clinical practice adheres to World Health Organization (WHO) diagnostic thresholds: fasting blood glucose $\ge 7.0\text{ mmol/L}$, random blood glucose $\ge 11.1\text{ mmol/L}$ with symptoms, or $\text{HbA1c} \ge 6.5\%$. Acute glycemic emergencies include severe hypoglycemia ($< 4.0\text{ mmol/L}$), Diabetic Ketoacidosis (DKA, characterized by metabolic acidosis, ketonemia, and Kussmaul respirations), and Hyperosmolar Hyperglycemic State (HHS, marked by extreme hyperglycemia $> 33.3\text{ mmol/L}$ and severe hyperosmolality without profound ketosis). Immediate nursing priorities involve aggressive fluid replacement, regular insulin infusion, and vigilant electrolyte monitoring.

---

Pathophysiology: Type 1 vs. Type 2 Diabetes Mellitus

Diabetes mellitus comprises distinct metabolic etiologies unified by hyperglycemia. A precise understanding of their distinct pathophysiologies is critical for clinical decision-making and licensing examinations.

Type 1 Diabetes Mellitus (T1DM)

• Etiology and Mechanism: T1DM is characterized by immune-mediated destruction of pancreatic beta cells within the islets of Langerhans, typically triggered by environmental factors in genetically susceptible individuals (associated with HLA-DR3 and HLA-DR4). This culminates in absolute insulin deficiency.
• Metabolic Consequence: Without insulin, target cells cannot take up glucose, triggering intracellular starvation. The counter-regulatory hormones (glucagon, cortisol, epinephrine, growth hormone) surge, stimulating accelerated glycogenolysis, gluconeogenesis, and profound lipolysis. The breakdown of adipose tissue releases free fatty acids, which the liver converts via beta-oxidation into acetoacetate and beta-hydroxybutyrate, causing ketoacidosis.
• Epidemiological Pattern: Typically manifests in children, adolescents, and young adults with acute onset of severe symptoms: polyuria, polydipsia, polyphagia, and rapid weight loss.

Type 2 Diabetes Mellitus (T2DM)

• Etiology and Mechanism: T2DM arises from a dual defect: peripheral insulin resistance (decreased tissue sensitivity to insulin in skeletal muscle, adipose tissue, and liver) paired with a progressive secretory defect of pancreatic beta cells.
• Metabolic Consequence: Because some endogenous insulin secretion persists, lipolysis is sufficiently restrained to prevent massive ketogenesis in ordinary circumstances. However, insulin resistance leads to unsuppressed hepatic glucose production and impaired peripheral uptake. Compensatory hyperinsulinemia eventually gives way to beta-cell exhaustion and progressive hyperglycemia.
• Epidemiological Pattern: Represents approximately 90–95% of diabetes cases worldwide and in Ghana. Most common in adults over 30 years old, strongly associated with central obesity, physical inactivity, urban dietary transitions, and positive family history.

---

Diagnostic Criteria and Clinical Thresholds

According to Ghana National Standard Treatment Guidelines and WHO/International Diabetes Federation (IDF) standards, diabetes mellitus is confirmed using standardized venous plasma glucose thresholds in SI units ($\text{mmol/L}$):

1. Fasting Plasma Glucose (FPG): $\ge 7.0\text{ mmol/L}$ ($126\text{ mg/dL}$) following an overnight fast of at least 8 to 12 hours.
2. Random Plasma Glucose (RPG): $\ge 11.1\text{ mmol/L}$ ($200\text{ mg/dL}$) in a patient presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss).
3. Two-Hour Oral Glucose Tolerance Test (OGTT): $\ge 11.1\text{ mmol/L}$ ($200\text{ mg/dL}$) two hours after an oral ingestion of $75\text{ g}$ anhydrous glucose dissolved in water.
4. Glycated Hemoglobin (HbA1c): $\ge 6.5\%$ ($48\text{ mmol/mol}$) utilizing an assay standardized to the National Glycohemoglobin Standardization Program (NGSP).

---

Oral Antidiabetic Pharmacotherapy

Oral antidiabetic agents form the backbone of pharmacological management in Type 2 Diabetes Mellitus when lifestyle modifications alone fail to achieve glycemic targets.

1. Biguanides: Metformin

• Mechanism of Action: Decreases hepatic gluconeogenesis, reduces intestinal absorption of glucose, and enhances peripheral insulin sensitivity in skeletal muscle.
• Key Benefits: Does not stimulate insulin secretion (zero intrinsic risk of hypoglycemia when used as monotherapy), weight-neutral or promotes modest weight loss, cardiovascular benefits.
• Major Adverse Effect & Risk: Lactic acidosis (rare but life-threatening). Common GI side effects include abdominal bloating, flatulence, metallic taste, and diarrhea.
• Renal Cautions: Metformin is excreted unchanged by the kidneys. It is contraindicated if estimated glomerular filtration rate (eGFR) falls below $30\text{ mL/min/1.73 m}^2$ and should not be initiated if eGFR is $30\text{--}45\text{ mL/min/1.73 m}^2$.
• Radiological Contrast Protocol: Metformin must be discontinued at the time of or prior to procedures requiring iodinated intravenous radiocontrast media and withheld for 48 hours post-procedure. It may only be resumed after renal function tests have been repeated and verified as stable, preventing contrast-induced acute tubular necrosis and subsequent fatal metformin accumulation.

2. Sulfonylureas: Glibenclamide & Glimepiride

• Mechanism of Action: Act directly as insulin secretagogues by binding to ATP-sensitive potassium channels on pancreatic beta-cell membranes, inducing depolarization, calcium influx, and exocytosis of preformed insulin granules independent of prevailing blood glucose levels.
• Major Adverse Effect: Severe, prolonged hypoglycemia and weight gain. Glibenclamide has active metabolites that accumulate in renal impairment; therefore, shorter-acting sulfonylureas (e.g., gliclazide) or lower-dose glimepiride are preferred in elderly individuals or patients with mild-to-moderate renal decline.
• Patient Education: Patients must be instructed to eat meals immediately after taking their medication and always carry fast-acting carbohydrates.

---

Insulin Formulations and Pharmacokinetics

Insulin replacement therapy is indispensable in Type 1 Diabetes Mellitus, advanced Type 2 Diabetes, gestational diabetes, and during acute hospitalizations or surgical interventions.

Injection Technique and Preventing Lipodystrophy

• Needle Angle and Depth: Subcutaneous injection should be administered at a $90^\circ$ angle into a pinched skin fold to ensure deposition into the subcutaneous tissue rather than underlying skeletal muscle. In emaciated or very lean patients, a $45^\circ$ angle is employed.
• Systematic Site Rotation: Injection sites encompass the abdomen (fastest, most predictable absorption rate), anterolateral thighs, upper outer arms, and upper buttocks. Patients must systematically rotate sites within the same anatomical region (e.g., leaving a $2.5\text{ cm}$ or 1-inch space between consecutive injections) for one to two weeks before moving to another region.
• Preventing Lipohypertrophy: Repeated injections into the same unrotated skin area produce fibrous, fatty subcutaneous nodules (lipohypertrophy). Injecting insulin into lipohypertrophic tissue results in delayed, erratic, and unpredictable drug absorption, causing alternating unexplained hyperglycemia and refractory hypoglycemia.

---

Acute Hypoglycemia Protocol ($< 4.0\text{ mmol/L}$)

Hypoglycemia is defined as a plasma glucose level $< 4.0\text{ mmol/L}$ ($70\text{ mg/dL}$). It represents a medical emergency that demands instantaneous intervention.

                             CLINICAL HYPOGLYCEMIA
                                 (< 4.0 mmol/L)
                                       |
                   +-------------------+-------------------+
                   |                                       |
          [CONSCIOUS PATIENT]                    [UNCONSCIOUS PATIENT]
                   |                                       |
           "Rule of 15":                        Protect Airway (Recovery Position)
     15 g Simple Carbohydrates                             |
 (3-4 sugar cubes / 150 mL juice)             IV Access Present?  ----+
                   |                                       |           |
       Wait 15 Mins -> Recheck                            YES          NO
                   |                                       |           |
    +--------------+--------------+                   50% Dextrose   Glucagon 1 mg
    |                             |                   (20-50 mL IV)     (IM / SC)
   < 4.0 mmol/L              >= 4.0 mmol/L
    |                             |
 Repeat 15 g Carbs      Complex Carb Snack / Meal

Clinical Manifestations: Adrenergic vs. Neuroglycopenic

1. Adrenergic / Autonomic Signs (Sympathetic Nervous System Surge): Manifest first as counter-regulatory catecholamines are released to raise blood glucose. Features include tremors, diaphoresis (cold sweats), tachycardia, palpitations, hunger, pallor, anxiety, and restlessness.
2. Neuroglycopenic Signs (CNS Glucose Deprivation): Manifest when the brain is starved of glucose. Features include confusion, irritability, slurred speech, visual disturbances, ataxia, bizarre behavior, drowsiness, seizures, and irreversible coma.

Emergency Management: Conscious vs. Unconscious Protocols

• Conscious Patient Protocol ("The Rule of 15"):

  1. Immediately administer $15\text{ g}$ of rapid-acting simple carbohydrate orally: 3–4 sugar cubes, 3 teaspoons ($15\text{ mL}$) of table sugar dissolved in water, or $150\text{ mL}$ of regular fruit juice/soda. Avoid milk, chocolate, or pastries (fat delays gastric emptying and glucose absorption).
  2. Rest for 15 minutes, then recheck capillary blood glucose.
  3. If blood glucose remains $< 4.0\text{ mmol/L}$, administer another $15\text{ g}$ of simple carbohydrate and re-evaluate in 15 minutes.
  4. Once blood glucose is $\ge 4.0\text{ mmol/L}$, provide a complex carbohydrate and protein snack (e.g., bread with peanut butter, a cup of porridge, or an advance of the scheduled meal) to sustain blood glucose and prevent secondary rebound hypoglycemia.

• Unconscious Patient Protocol (Impaired Swallowing / Coma):

  1. Do not administer anything orally due to extreme aspiration risk.
  2. Maintain patent airway and position the patient in the lateral recovery position.
  3. Establish IV access: Administer $20\text{--}50\text{ mL}$ of $50\%$ Dextrose in Water (D50W) as a slow intravenous push over 3 to 5 minutes through a freely patent large-bore cannula (extravasation causes chemical tissue necrosis).
  4. If IV access is unavailable: Administer $1\text{ mg}$ Glucagon intramuscularly (IM) or subcutaneously. Turn the patient on their side because glucagon frequently induces nausea and vomiting upon consciousness restoration.

---

Hyperglycemic Crises: DKA vs. HHS

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) are severe, life-threatening decompensations requiring urgent intensive nursing interventions.

---

Emergency Nursing Management Protocol for DKA and HHS

The management of DKA and HHS follows structured clinical resuscitation protocols prioritizing fluid resuscitation, regular insulin delivery, potassium correction, and electrolyte stabilization.

1. Fluid Resuscitation (Volume Restoration First)

• Initial Fluid: Infuse $0.9\%$ Normal Saline ($1\text{ L/hr}$ initially or $15\text{--}20\text{ mL/kg/hr}$) for the first 1 to 2 hours to expand effective intravascular volume, reverse hypovolemic shock, and restore renal perfusion.
• Secondary Fluid: Once hemodynamically stable, adjust IV fluids to $0.45\%$ Normal Saline (if corrected sodium is normal or high) or continue $0.9\%$ Normal Saline (if sodium is low) at $250\text{--}500\text{ mL/hr}$.
• Preventing Cerebral Edema: When blood glucose drops to $14.0\text{ mmol/L}$ ($250\text{ mg/dL}$) in DKA (or $16.7\text{ mmol/L}$ [$300\text{ mg/dL}$] in HHS), immediately switch or add $5\%$ Dextrose in $0.45\%$ Saline (or $5\%$ Dextrose in Water). This maintains blood glucose between $11.0\text{--}14.0\text{ mmol/L}$ while insulin infusion continues to clear ketoacids, preventing sudden osmotic shifts that trigger fatal cerebral edema.

2. Continuous Intravenous Insulin Infusion

• Administer Regular (soluble) insulin via continuous IV infusion at a fixed rate of $0.1\text{ units/kg/hr}$.
• Target a gradual reduction in blood glucose of $3.0\text{--}4.0\text{ mmol/L/hr}$ ($50\text{--}75\text{ mg/dL/hr}$). Precipitous falls in plasma osmolality must be avoided.

3. Potassium Replacement Protocol

• Serum Potassium Check: Insulin drives potassium into intracellular compartments, precipitating lethal cardiac dysrhythmias.
• Rule 1: If serum potassium is $< 3.3\text{ mmol/L}$, hold insulin and infuse IV potassium chloride ($20\text{--}40\text{ mEq/hr}$) until $\text{K}^+ > 3.3\text{ mmol/L}$.
• Rule 2: If serum potassium is between $3.3\text{--}5.2\text{ mmol/L}$, add $20\text{--}30\text{ mEq}$ of potassium chloride to each liter of IV replacement fluid to keep serum potassium between $4.0\text{--}5.0\text{ mmol/L}$.
• Rule 3: If potassium is $> 5.2\text{ mmol/L}$, do not administer potassium, but monitor levels every 2 hours alongside continuous cardiac telemetry.